

- Tumor(s) (*Continued*)
 in inflammation, 71, 93
 local and hormonal effects of, 330
 malignant. *See* Cancer
 molecular profiles of, 335-336
 progression, 281
 types, 337f
 of unknown origin, 1203-1204
 Tumor antigens, 310-312, 311f
 Tumor cells, circulating, 334
 Tumor giant cells, 270
 Tumor-like lesions, 473-481, 960, 969,
 1196-1207, 1207b, 1218
 Tumor necrosis factor (TNF)
 in disseminated intravascular
 coagulation, 663-664
 in inflammation, 86-87
 Tumor suppressive miRs, 320
 Tumor suppressor genes, 290-300, 291t,
 299b-300b
 ABC as, 296-297, 297f
 in APC/ β -catenin signaling pathway,
 296-297
 NF1 as, 298
 NF2 as, 298
 PTCH1 as, 298-299
 PTEN as, 298
 RB as, 292-293, 293b, 293f
 silencing of, by local hypermethylation of
 DNA, 319
 in TGF- β pathway, 298
 TP53 as, 293-296, 295f, 296b
 VHL as, 299
 WTI as, 298
 Tunica vaginalis, lesions of, 980
 Turban tumor, 1152
 Turbulence, and thrombosis, 14
 Turcot syndrome, 1316
 Turner syndrome, 166-167, 167f
 Turnover, collagen, 500
 Twin placentas, 1036-1037, 1037f
 Twin-twin transfusion syndrome, 1036-1037
 TWIST, in metastasis, 309
 "Two-hit" hypothesis, of oncogenesis, 290
 Type I pneumocytes, 670
 Type II pneumocytes, 670
 Typhus fever, 385b, 385f
 Tzanck test, 729b
- U**
 UBE3A gene, 173
 Ubiquitin, 14
 Ubiquitin-proteasome pathway, in atrophy,
 37
 Ulcer(s), 91, 92f
 Hunner, 962-963
 peptic, in Zollinger-Ellison syndrome
 (gastrinomas), 1121
 skin, healing of, 108f
 Ulceration, 1143t
 Ulegyria, 1259
 Ultraviolet rays, in cancer, 324-325
 Ultraviolet (UV) light
 in squamous cell carcinoma, 1155
 in systemic lupus erythematosus, 221
 Uncinate herniation, 1255
 Unconjugated hyperbilirubinemia, 854t
 Uncontrolled proliferation, 19
 Undernutrition, in Global Burden of
 Disease, 404-405
 Undifferentiated pleomorphic sarcoma
 (UPS), 1224, 1224b, 1224f
 Unfolded protein response, 12, 57-58, 57f,
 152
 Uniparental disomy, 173
 United States, 570
 Up-regulation, of cyclin D1, 602-603
 Upper airways, disorders of, 735-740
 of larynx, 738-740, 739f, 740b
 of nasopharynx, 736, 738b
 necrotizing lesions as, 736
 of nose, 735-736
 tumors of nose, sinuses, and nasopharynx
 as, 737-738
 Urachal cysts, 962
 Urachus, 962
 Urate nephropathy, 936-937, 937f
Ureaplasma urealyticum, 994
 Uremia, 898, 899t
 Uremic neuropathy, 1233
 Ureter(s), 960-961
 anatomy of, 959-960
 congenital anomalies of, 960
 dilation of, 960
 disorders of, 961b
 diverticula of, 960
 double and bifid, 960
 hydro-, 960-961
 inflammation of, 960, 960f
 obstructive lesions of, 960-961, 961t
 sclerosing retroperitoneal fibrosis of, 961
 tumors and tumor-like lesions of, 960,
 961f
 Ureteral obstruction, 960-961, 961t
 Urethritis, 960, 960f
 cystica, 960, 960f
 follicularis, 960
 Ureteropelvic junction (UPJ) obstruction,
 960
 Urethra, 969
 anatomy of, 959
 carcinoma of, 969, 969f
 inflammation of, 969
 tumor and tumor-like lesions of, 969, 969f
 Urethral caruncle, 969
 Urethritis, 969
 gonococcal, 969
 nongonococcal, 969
 Uric acid, metabolism of, 1215
 Uric acid stones, 951t, 952
 Urinary bladder, 961-969
 anatomy of, 959
 congenital anomalies of, 961-962, 962f
 inflammation of, 962-963, 963f
 metaplastic lesions of, 963-964
 neoplasms of, 964-969, 964t
 mesenchymal tumors, 968
 secondary, 968-969
 urothelial tumors, 964-968, 965b-967b,
 965f, 967t
 obstruction of, 969, 969f
 morphology of, 969b
 Urinary tract infection, 899, 930-935, 930f
 Urinary tract obstruction, 931, 950-952,
 950b, 950f
 Urinary tract stones, in
 hyperparathyroidism, 1102b-1103b
 Urogenital sinus, 992, 992f
 Urogenital tract, infections via, 342t,
 343-344
 Urolithiasis, 951-952, 951t, 952b
 Urothelial carcinoma, 960, 961f
 Urothelial tumors, 964-968
 carcinoma as
 adeno-, 967
 clinical course of, 967-968
 epidemiology and pathogenesis of,
 964-965
 high-grade, 966, 966f
 invasive, 966-967, 967f
- Urothelial tumors (Continued)*
 low-grade, 966, 966f
 mixed, 967
 papillary, 965f, 966
 of low malignant potential, 966
 precursor lesions to, 964
 in situ, 964, 965f, 966, 967f
 small-cell, 967
 squamous cell, 967
 staging of, 966-967, 967t
 variants of, 967
 grading of, 964, 964t
 morphology of, 965b-967b, 965f, 966f,
 967f
 noninvasive
 flat, 964, 965f
 papillary, 964, 965f
 pagetoid spread, 966
 papillary
 carcinoma as, 965f
 of low malignant potential, 966
 noninvasive, 964
 papilloma as, 964-966, 966f
 Urothelium, 959
 Urticaria, 1162, 1162b, 1162f
 pigmentosa, 1160, 1161b
 Urticarial allergic reactions, 665
 Urushiol, 210-211
 USP6, 1204
 Uterine leiomyoma, 1019-1020
 Uteroplacental insufficiency, 457
 Uterus
 body of, 1007-1021
 leiomyoma of, 1021f
 physiologic hypertrophy of, 34, 34f
 Uveitis, 1330-1331
- V**
 Vacuolization, 1143t
 Vagina, 1000-1001
 developmental anomalies of, 1000
 embryonal rhabdomyosarcoma, 1001
 premalignant and malignant neoplasms
 of, 1000-1001
 squamous cell carcinoma of, 1000
 Vaginal adenosis, 1000
 Vaginal intraepithelial neoplasia, 1000-
 1001
 Vaginosis, bacterial, 994
 Valvular heart disease, 554-563, 564b
 aortic stenosis as, 537-538
 Variable expressivity, 140
 Variant Creutzfeldt-Jakob disease, 1282,
 1282b
 Variant surface glycoprotein (VSG), in
 African trypanosomiasis, 394
 Varicella-zoster virus (VZV), 358-359, 359f
 encephalitis due to, 1276-1277
 peripheral neuropathy in, 1232
 Varices, of brain, 1271b
 Varicocele, 980
 Varicose veins, 514
 Vasa vasorum, 502
 Vascular amyloidosis, 262
 Vascular anomalies, in blood vessels, 485
 Vascular congestion, in inflammation, 74
 Vascular diseases
 atherosclerosis in, 491
 hypertensive, 487-491
 renal, 938-944
 diffuse cortical necrosis as, 944, 944b,
 944f
 renal artery stenosis as, 940-941,
 940b-941b
 renal infarcts as, 944, 944b